Hasil Pencarian - Toshihiko Doi

  • Menampilkan 1 - 18 hasil dari 18
Perbaiki Hasil
  1. 1
    Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

    Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment oleh Yasuko Tada, Yosuke Togashi, Daisuke Kotani, Takeshi Kuwata, Eichi Sato, Akihito Kawazoe, Toshihiko Doi, Hisashi Wada, Hiroyoshi Nishikawa, Kohei Shitara

    Diterbitkan 2018-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study

    Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study oleh Toshihiko Doi, Noboru Yamamoto, Yoichi Naito, Yasutoshi Kuboki, Takafumi Koyama, Yongzhe Piao, Naoto Tsujimoto, Hiroya Asou, Koichi Inoue, Shunsuke Kondo

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites

    A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites oleh Hiroshi Matsumoto, Akihito Kawazoe, Kaoru Shimada, Shota Fukuoka, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Atsushi Ohtsu, Takayuki Yoshino, Toshihiko Doi, Kohei Shitara

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

    Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer oleh Saori Mishima, Akihito Kawazoe, Yoshiaki Nakamura, Akinori Sasaki, Daisuke Kotani, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino, Takeshi Kuwata, Akihito Tsuji, Kohei Shitara

    Diterbitkan 2019-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    PD‐1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study

    PD‐1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study oleh Yasutoshi Kuboki, Takafumi Koyama, Nobuaki Matsubara, Yoichi Naito, Shunsuke Kondo, Kenichi Harano, Kan Yonemori, Kiyotaka Yoh, Yuan Gu, Tetsuya Mita, Xuejun Chen, Eiji Ueda, Noboru Yamamoto, Toshihiko Doi, Toshio Shimizu

    Diterbitkan 2024-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer

    Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer oleh Saori Mishima, Akihito Kawazoe, Yasutoshi Kuboki, Takashi Kojima, Toshihiko Doi, Takayuki Yoshino, Kohei Shitara, Yoshiaki Nakamura, Kentaro Sawada, Hiroya Taniguchi, Daisuke Kotani, Akinori Sasaki, Testuya Eto, Mashiro Okunaka, Tetsuo Akimoto

    Diterbitkan 2020-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer

    Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer oleh Takahiro Ishii, Akihito Kawazoe, Akinori Sasaki, Saori Mishima, Sawada Kentaro, Yoshiaki Nakamura, Daisuke Kotani, Yasutoshi Kuboki, Hiroya Taniguchi, Takashi Kojima, Toshihiko Doi, Takayuki Yoshino, Takeshi Kuwata, Genichiro Ishii, Kohei Shitara

    Diterbitkan 2020-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab

    p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab oleh Shota Fukuoka, Yoshikatsu Koga, Mayumi Yamauchi, Shigehiro Koganemaru, Masahiro Yasunaga, Kohei Shitara, Toshihiko Doi, Takayuki Yoshino, Toshio Kuronita, Brian Elenbaas, Pamela Wahra, Hong Zhang, Lindsey Crowley, Molly H. Jenkins, Anderson Clark, Takashi Kojima

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study

    Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicent... oleh Toshihiko Doi, David Tai, Dong-Wan Kim, F Stephen Hodi, Sofie Wilgenhof, Catherine Sabatos-Peyton, Giuseppe Curigliano, Chia-Chi Lin, Armando Santoro, Alexandros Xyrafas, Nicolas Mach, Sebastian Szpakowski, Shripad Chitnis, Sabine Gutzwiller, Alessandro Pastore

    Diterbitkan 2024-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer

    Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer oleh David S. Hong, Ajay K. Gopal, Alexander N. Shoushtari, Sandip P. Patel, Aiwu R. He, Toshihiko Doi, Suresh S. Ramalingam, Amita Patnaik, Shahneen Sandhu, Ying Chen, Craig B. Davis, Timothy S. Fisher, Bo Huang, Kolette D. Fly, Antoni Ribas

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiency

    A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiency oleh Shinji Kohsaka, Shigehiro Yagishita, Yukina Shirai, Yusuke Matsuno, Toshihide Ueno, Shinya Kojima, Hiroshi Ikeuchi, Masachika Ikegami, Rina Kitada, Ken-ichi Yoshioka, Kohta Toshimitsu, Kimiyo Tabata, Akira Yokoi, Toshihiko Doi, Noboru Yamamoto, Takashi Owa, Akinobu Hamada, Hiroyuki Mano

    Diterbitkan 2024-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

    Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer oleh Janice M. Mehnert, Andrea Varga, Marcia S. Brose, Rahul R. Aggarwal, Chia-Chi Lin, Amy Prawira, Filippo de Braud, Kenji Tamura, Toshihiko Doi, Sarina A. Piha-Paul, Jill Gilbert, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Bhumsuk Keam

    Diterbitkan 2019-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab

    Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab oleh Yuka Maeda, Hisashi Wada, Daisuke Sugiyama, Takuro Saito, Takuma Irie, Kota Itahashi, Kodai Minoura, Susumu Suzuki, Takashi Kojima, Kazuhiro Kakimi, Jun Nakajima, Takeru Funakoshi, Shinsuke Iida, Mikio Oka, Teppei Shimamura, Toshihiko Doi, Yuichiro Doki, Eiichi Nakayama, Ryuzo Ueda, Hiroyoshi Nishikawa

    Diterbitkan 2021-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect.

    Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate s... oleh Hiro Takahashi, Kimie Sai, Yoshiro Saito, Nahoko Kaniwa, Yasuhiro Matsumura, Tetsuya Hamaguchi, Yasuhiro Shimada, Atsushi Ohtsu, Takayuki Yoshino, Toshihiko Doi, Haruhiro Okuda, Risa Ichinohe, Anna Takahashi, Ayano Doi, Yoko Odaka, Misuzu Okuyama, Nagahiro Saijo, Jun-ichi Sawada, Hiromi Sakamoto, Teruhiko Yoshida

    Diterbitkan 2014-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors

    First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors oleh Kohei Shitara, Satoshi Ueha, Shigeyuki Shichino, Hiroyasu Aoki, Haru Ogiwara, Tetsuya Nakatsura, Toshihiro Suzuki, Manami Shimomura, Toshiaki Yoshikawa, Kayoko Shoda, Shigehisa Kitano, Makiko Yamashita, Takayuki Nakayama, Akihiro Sato, Sakiko Kuroda, Masashi Wakabayashi, Shogo Nomura, Shoji Yokochi, Satoru Ito, Kouji Matsushima, Toshihiko Doi

    Diterbitkan 2019-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

    First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors oleh Toshihiko Doi, John A Thompson, Omid Hamid, Adi Diab, Siwen Hu-Lieskovan, Jeffrey Chou, Jeffrey S Wasser, Patrick A Ott, Jean-Philippe Spano, Willeke Ros, Alison Forgie, Wenjing Yang, Ferry A L M Eskens, Alberto A Chiappori, Eric Angevin, Naiyer A Rizvi, Cen Guo, Anthony B El-Khoueiry

    Diterbitkan 2022-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens

    Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens oleh Yukie Kashima, Yosuke Togashi, Shota Fukuoka, Takahiro Kamada, Takuma Irie, Ayako Suzuki, Yoshiaki Nakamura, Kohei Shitara, Tatsunori Minamide, Taku Yoshida, Naofumi Taoka, Tatsuya Kawase, Teiji Wada, Koichiro Inaki, Masataka Chihara, Yukihiko Ebisuno, Sakiyo Tsukamoto, Ryo Fujii, Akihiro Ohashi, Yutaka Suzuki, Katsuya Tsuchihara, Hiroyoshi Nishikawa, Toshihiko Doi

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)

    Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181) oleh John Powderly, Alexander Spira, Shunsuke Kondo, Toshihiko Doi, Jason J. Luke, Drew Rasco, Bo Gao, Minna Tanner, Philippe A. Cassier, Anas Gazzah, Antoine Italiano, Diego Tosi, Daniel E. Afar, Apurvasena Parikh, Benjamin Engelhardt, Stefan Englert, Stacie L. Lambert, Sreeneeranj Kasichayanula, Sven Mensing, Rajeev Menon, Gregory Vosganian, Anthony Tolcher

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: